Loges, S., Heuser, M., Chromik, J., Sutamtewagul, G., Kapp-Schwoerer, S., Crugnola, M., Renzo, N. D., Lemoli, R., Mattei, D., Fiedler, W., Alvarado-Valero, Y., Ben-Batalla, I., Waizenegger, J., Rieckmann, L., Janning, M., Collienne, M., Imbusch, C. D., Beumer, N., Micklem, D., Nilsson, L. H., Madeleine, N., McCracken, N., Oliva, C., Gorcea-Carson, C., Gjertsen, B. T. (2025). Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial. Nature Communications. https://doi.org/10.1038/s41467-025-58179-6